Ultime notizie per Exicure (NASDAQ:XCUR) Azioni

Exicure

Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.

XCUR

Cinque azioni da tenere d&#39;occhio oggi, inclusi Darden Restaurants e FedEx, con risultati trimestrali pronti a sorprendere.

Pre-market: 5 titoli da monitorare oggi C

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

CODA

RFIL

VNCE

Coda Octopus, Exicure e altri titoli in movimento nel pre-market: ecco cosa aspettarsi oggi 16 settembre 2024.

Pre-market: 5 titoli da monitorare oggi, 16 settembre 2024

Exicure Inc

Curate

<h3>Gainers</h3>
<ul>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares moved upwards by 41.9% to $0.36 during Thursday's regular session. The company's market cap stands at $2.7 million. </li>
<li>MultiSensor AI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSAI#NASDAQ">MSAI</a>) stock increased by 11.96% to $1.88. The company's market cap stands at $44.8 million. </li>
<li>Akoustis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTS#NASDAQ">AKTS</a>) stock increased by 10.8% to $0.08. The market value of their outstanding shares is at $8.7 million. </li>
<li>Phunware (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHUN#NASDAQ">PHUN</a>) stock moved upwards by 10.7% to $3.93. The market value of their outstanding shares is at $44.5 million. </li>
<li>Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) stock increased by 10.37% to $2.98. The company's market cap stands at $359.7 million. </li>
<li>Atomera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATOM#NASDAQ">ATOM</a>) stock increased by 10.21% to $3.56. The market value of their outstanding shares is at $98.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Cemtrex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CETX#NASDAQ">CETX</a>) stock declined by 25.8% to $0.53 during Thursday's regular session. </li>
<li>E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) stock declined by 18.88% to $3.31. The company's market cap stands at $1.0 billion. As per the news, the Q2 earnings report came out yesterday. </li>
<li>XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) stock decreased by 14.82% to $5.52. The market value of their outstanding shares is at $402.8 million. </li>
<li>NiSun Intl Enterprise Dev (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NISN#NASDAQ">NISN</a>) shares declined by 12.23% to $12.49. The company's market cap stands at $49.3 million. </li>
<li>Wetouch Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETH#NASDAQ">WETH</a>) stock declined by 11.43% to $1.86. The market value of their outstanding shares is at $22.1 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) stock declined by 11.35% to $0.78. The market value of their outstanding shares is at $76.5 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AIXI

AKTS

ATOM

CETX

ETWO

LWLG

MLGO

Infrared Cameras Holdings, Inc. - Common Stock

MSAI

NISN

PHUN

WETH

12 Information Technology Stocks Moving In Thursday's Intraday Session

Morgan Stanley analyst Michael Cyprys maintains Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) with a Equal-Weight and raises the price target from $136 to $162.

Price Target

Analyst Ratings

ARES

Morgan Stanley Maintains Equal-Weight on Ares Management, Raises Price Target to $162

<a href="https://www.youtube.com/watch?v=vJ8aEO6ggOs" title="https://www.youtube.com/watch?v=vJ8aEO6ggOs">https://www.youtube.com/watch?v=vJ8aEO6ggOs</a>

AMD Executive Launches New MI325X AI Chip

<h4>Key Takeaways:</h4>
<ul>
<li>Zephyrm Bioscience&rsquo;s losses have increased by more than two times year-on-year to 237 million yuan in the first half of 2024</li>
<li>The company has only four products, with only one product in Phase II clinical trials, far from commercialization</li>
</ul>
By Fai Pui
Stock markets in the mainland China and Hong Kong have once again become active under a series of policy packages to rescue the market. More and more companies are planning go public on the Hong Kong Stock Exchange for fund raising in the fourth quarter, hoping to obtain a higher valuation amid this stock market frenzy.
Founded in 2017,&nbsp;Zephyrm Bioscience Ltd., a young stem-cell drug researcher, developer and producer, filed for a&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2024/106833/documents/sehk24093002559.pdf">listing application</a>&nbsp;to the Hong Kong Stock Exchange on the last day of September, with CICC as the exclusive sponsor.
Like most biotech companies at their early stages, Zephyrm currently has no commercialized product and thus no revenue. Instead, according to the prospectus, the company has been knee deep in losses pile-up, rising from about 173 million yuan ($24.4 million) in 2022 to 196 million yuan in 2023, and to whopping 237 million yuan in the first half of 2024, which has surged 210% over the same period in 2023.
The sharp increase in losses was mainly driven by the skyrocketing administrative expenses in the first half of 2024, from 18.37 million yuan in 2023 to 143 million yuan. Notably, 114 million yuan of share-based compensation expenses, which had not been incurred in the past two years, is also included in the administrative cost. Meanwhile, R&amp;D is the second biggest cause of its mounting losses. While the relevant spending has increased from 66.31 million yuan in 2022, to 103 million yuan in 2023, now it has already been up to 58.52 million yuan in the first half of 2024, marking a surprising increase of 71.4% over the same period last year.
Mainly engaging in the development of innovative cell therapy products derived from pluripotent stem cells (PSC) that can treat a variety of diseases, Zephyrm is one of the first companies in China and even the world to develop PSC-derived cell therapy products. According to Frost &amp; Sullivan, the company is one of the first in China to be approved for an investigational new drug (IND) application for PSC-derived cell therapy, and the only company in China with multiple PSC-derived cell therapy assets in Phase II clinical trials.
According to the prospectus, Zephyrm&rsquo;s current product portfolio includes its core product ZH901 and its major products ZH903, ZH902 and ZH906. ZH901 is a M-cell therapy product that is being studied for the treatment of injuries and inflammations as well as degenerative diseases. Its clinical development in China for various indications has entered phase two. About 100 patients have been treated with ZH901 through intravenous infusion or intra-articular administration in the knee joint in multiple clinical trials, but none of them experienced serious adverse effects.
However, all these other three products are still in the early clinical stage. ZH903 is a mDAP cell therapy product for the treatment of Parkinson&rsquo;s disease; ZH902 is a RPE cell therapy product for the treatment of dry AMD to improve patients&rsquo; impaired vision; and ZH906 is a CEnC therapy product for the treatment of corneal endothelial dysfunction.
In addition, Zephyrm has developed a PSC-derived cell therapy products development platform (PROF), which comprises three independent platforms, namely, Pluripotent Stem Cell Seed Platform (PROF-seed), Vital Functional Cell Development Platform (PROF-function), and Formulation Optimization Platform (PROF-formulator). This unique set of integrated technology platforms is designed to help the company develop products more effectively.
In order to support future commercialization, Zephyrm has established a factory in Beijing with a total construction area of approximately 2,380 square meters. It will be able to produce approximately 35,000 injections of cell therapy products annually to support the company&rsquo;s clinical development and early commercialization. The company is also planning to establish a manufacturing plant in Zhongshan City, Guangdong Province, with a total construction area of approximately 150,000 square meters and an estimated annual production capacity of approximately 500,000 injections of cell therapy products to support commercial production. The new expansion projects will officially commence production in 2030.
Therefore, it is not surprising to know the funds raised in the listing, if succeeded, would be used for the factory in Zhongshan City, and for product R&amp;D and clinical research.
<h3>Only 78 Million Yuan Of Cash In Hand</h3>
However, the nearly empty pocket for R&amp;D is the biggest reason for Zephyrm&rsquo;s enthusiasm over IPO. As of the end of June 2024, it only has 78.26 million yuan in cash and cash equivalents, a significant decrease of 53% compared to the end of 2023. However, on the one hand, its R&amp;D expenditure throughout the year of 2023 already reached 103 million yuan, already amounted to 58.52 million yuan in the first half of 2024. On the other hand, this biotech company still has no commercial products or obtain any government subsidies in the first half of 2024. That means turning to the capital market for funds to support R&amp;D becomes the only way to go.
In addition, early investors are also eager to cash out. According to the prospectus, the company launched an angel round of financing in 2019, receiving funds from investors including Zhongke Chuangxing Hard Technology, Zhonghe Tiancheng Entrepreneur Management, Xi&rsquo;an Yingshi Fukun Biotechnology and Shandong Haoyang Biological Engineering. Back then, it raised 150 million yuan at the cost per share of 3.87 yuan.
One year later, it carried out the A-round financing with the cost per share increasing to 8.3 yuan, pocketing another 160 million yuan from investors such as Beijing Guoke Dingzhi Equity Investment, Beijing Yuanqing Bencao Equity Investment and Beijing Yingshi Biotechnology. Then it conducted another round of financing in the B, B+, and B++ rounds at 9.38 yuan per share between 2022 to 2024. Investors include Beijing Yingsheng Fukun Biotechnology, Jiaxing Chenyue Equity Investment Partnership and Beijing Yingshi Biotechnology. The three rounds of financing have raised 656 million yuan in total for Zephyrm, and all early investors are in a 180-day lock-up period.
With about 20 million yuan invested for 0.89% shares by Beijing Xietai Management Partnership, Zephyrm should be worth about 2.25 billion yuan. However, Hong Kong Stock Exchange is no short of biotechnology stocks. Investing in biotechnology companies is basically placing a bet on whether the company&rsquo;s products can eventually pass clinical trials and successfully enter commercialization.
Now the show is finally heating up again in Hong Kong, and the IPO is filled with hustling and bustling again. The share price of&nbsp;TYK Medicines&nbsp;(2410.HK), a biotech stock listed in August, has risen by about 150% so far. If Zephyrm can pass the listing hearing, investors chasing short-term profits may flock in to the subscription.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Asia

Biotech

General

Increasing Losses Prompt Zephyrm Bioscience To Seek Funds Through IPO

Morgan Stanley analyst Michael Cyprys maintains Apollo Global Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) with a Equal-Weight and raises the price target from $111 to $137.

Morgan Stanley Maintains Equal-Weight on Apollo Global Management, Raises Price Target to $137

Momentum trading involves buying rising stocks with the idea that they will continue rising. While reminiscent of the greater fools theory, momentum trading is more than buying high and selling high. Good momentum trades combine factors that help ensure the market is bullish and capable of continuing the uptrend with catalysts to drive the market even higher.&nbsp;
The stocks in this article do just that: they combine numerous variables, including fundamental quality, an outlook for growth, analysts and institutional support, and catalysts for additional upside. A starting place to find such stocks in the future? MarketBeat&#39;s list of Most Upgraded Stocks and the Momentum Alerts feature.
<h2>Meta Platforms to Hit $660 in 2025</h2>
Meta Platforms&nbsp;has been a hot momentum trade for the last two years. The stock hit bottom in 2023, and the rebound was accelerated by the &quot;year of efficiency&quot; and then AI-enabled improvements in user, ad display, and revenue-per-ad metrics. The net result is a resurgence in growth, sustained in the high double-digits in 2024 expected to continue in 2025. Highlights from 2024 suggest the 2025 consensus estimates are low, providing a potential tailwind for the market in the form of outperformance and analyst upgrades to revenue and earnings targets.&nbsp;
Analysts support this market. The action in Q3 lifted the stock into the #1 position on MarketBeat&#39;s list of Most Upgraded Stocks, with 35 positive revisions in the 90 days leading into October. The analysts rate the stock as a Moderate Buy and have aggressively increased their stock price targets.&nbsp;
The consensus target assumes fair value near the early October highs but has been up by nearly 100% in the last 12 months and is rising. The freshest targets include initiated coverage by Pivotal Research, which put the stock price at $780 compared to the $600 consensus figure. Because most targets issued since mid-summer are at or above the consensus, Meta will likely continue to move higher in calendar Q4.&nbsp;
The next visible catalyst for Meta Platforms is the FQ3 earnings report due at the end of the month. The analysts have set the bar high with revisions, but the consensus may still underestimate reality, expecting a sequential slowdown in YoY growth. Meta Platforms has outpaced top and bottom-line consensus forecasts for six consecutive quarters.
<img alt="META stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009095008_chart-meta-1092024.png" style="height:423px; width:917px" />
<h2>Palo Alto Networks: Growth, Cash Flow, Analysts, and Nancy Pelosi Support This Stock</h2>
Analysts&#39; activity lifted Palo Alto Networks (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/panw#NASDAQ">PANW</a>) into the 2nd position on the list of Most Upgraded Stocks in late summer. The activity includes numerous revisions and an initiated coverage, pegging the stock at Moderate Buy with a high likelihood of advancing above the consensus price target. The consensus implies fair value near the current levels, but the revisions trend leads to the high-end range with high conviction. More than 80% of the targets issued in calendar Q3 are above consensus, with most suggesting a minimum of 5% upside from the critical resistance target.&nbsp;
The reason analysts are bullish is the company results. Sentiment dimmed when the plaformization plan was announced, but the results since have been better than expected. They reveal underlying business strength and a faster-than-expected impact from the shift, expected to drive long-term growth and wider margins. The next visible catalyst is the FQ1 results due in mid-November. Analysts are raising the bar with revisions, but consensus underestimates business strength, expecting a sequential decline in revenue and earnings.&nbsp;
<img alt="Palo Alto Networks PANW stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009095016_chart-panw-01092024.png" style="height:423px; width:917px" />
<h2>Oracle: The New Go-To Source for Enterprise Cloud Database</h2>
Oracle&#39;s (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/orcl#NYSE">ORCL</a>) multi-year to cloud-based software services kicked into high gear this year. The company has emerged as a leader in AI infrastructure and services, as evidenced by a deal with Amazon. The Amazon deal will embed Oracle&#39;s enterprise-quality services into its cloud, making it the leading choice among the three dominant cloud hyperscalers.&nbsp;
Results in 2024 drive an analyst upgrade cycle, and the revisions are robust. The activity resulted in Oracle shooting up the rankings, breaking into the top ten with 6th position in early October. The consensus target lags the market but supports the price action due to the revision trend. The consensus is up 35% since October 2023, and revisions lead to the high-end range above $200, a 15% upside for investors. The next visible catalyst is the FQ2 results due in early December, although results from other critical AI players may also drive the market.<img alt="Oracle ORCL stock chart" class="aligncenter" src="https://www.marketbeat.com/logos/articles/med_20241009101502_chart-orcl-1092024.png?1728486902436" style="height:423px; width:917px" />
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-momentum-trades-for-october-with-ample-upside-ahead/">3 Momentum Trades for October&nbsp;With Ample Upside Ahead</a>&quot; first appeared on MarketBeat.

Large Cap

Tech

ORCL

PANW

3 Momentum Trades for October With Ample Upside Ahead

KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>, TSXV:<a class="ticker" href="https://www.benzinga.com/stock/KWE#TSXV">KWE</a>) ("KWESST" or the "Company") announces that its board of directors (the "Board") has authorized a plan to proceed with a consolidation of its outstanding common shares (each, a "Share") on the basis of ten (10) pre-consolidation Shares for each one (1) post-consolidation Share (the "Consolidation"). The Consolidation is subject to approval of the TSX Venture Exchange (the "Exchange"). The Company believes that the Consolidation is in the best interests of shareholders as it will allow the Company to ensure continued compliance with the NASDAQ Stock Market minimum bid price requirements. Accordingly, the Company opted not to hold its special meeting of shareholders pursuant to which it was seeking a consolidation of its Shares on a greater basis.
As at the date hereof, there are a total of 15,791,742 Shares issued and outstanding. Assuming no other change to the issued and outstanding Shares, if the Consolidation is put into effect, a total of 1,579,174 Shares, subject to adjustments for rounding, would be issued and outstanding.

Stock Split

TSXV:KWE

KWESST Micro Systems Announces Proposed 10-For-1 Share Consolidation

Lake Street analyst Rob Brown maintains Applied Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) with a Buy and raises the price target from $7 to $11.

APLD

Lake Street Maintains Buy on Applied Digital, Raises Price Target to $11

AMD Executive Says Expects Data Center AI Market To Grow To $500B In 2028

WIIM

FIVN

Five9 shares are trading higher after the company announced it expanded its global presence through new data centers in Delhi and Mumbai. Additionally, the company secured a DOT certification to offer access and long-distance services in India.

Lake Street analyst Robert Brown maintains LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) with a Buy and lowers the price target from $9 to $6.

LIQT

Lake Street Maintains Buy on LiqTech Intl, Lowers Price Target to $6

Cinemark Holdings shares are trading higher after Roth MKM and Wells Fargo raised their respective price targets on the stock.

Looking at gold, it remains in a very strong uptrend, though it has paused due to the impressive recovery in the US dollar. The dollar could continue to see more upside, especially given that inflation came in a bit stickier at 2.4% rather than the expected 2.3%. However, even if the dollar strengthens after the next pullback, there's still a chance that gold will resume its uptrend. Remember, if inflation remains elevated and doesn't trend downward, gold could be seen as an inflation hedge. Additionally, gold tends to perform well during times of geopolitical risk, like the current issues in the Middle East.
In terms of the wave count, we're seeing a very nice three-wave retracement in gold back to the 2600 level, which is a key level from mid-September when the Fed cut rates by 50 basis points. This level could now serve as a good area for the next swing to the upside. Ideally, this push higher could occur in the fifth wave, especially if the price breaks above the 2635 resistance, markets as bullish level, which could open the door to 2700.
On the downside, the channel support is critical, but the most important level for identifying a potential top would be a break below 2532. Only then could we say the top is in place, as this would invalidate the uptrend based on Elliott Wave rules, which dictate that wave 4 must not fall into the territory of wave 1.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="800" height="751" src="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png" alt="" class="wp-image-2172" style="width:624px" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1.png 800w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-300x282.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2024/10/10161026/gold-4h-800x751-1-768x721.png 768w" sizes="(max-width: 800px) 100vw, 800px" /></figure>
Trade Well,
Grega Horvat
Forex Analytix

Commodities

Gold Has More Upside After This Pullback

Taiwan Semiconductor Manufacturing Co. Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) and Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) are currently competing for a seat at an elite table: The <a href="https://www.benzinga.com/news/24/07/39674237/tsmcs-market-cap-hits-1-trillion-whats-going-on-with-the-stock">exclusive trillion-dollar club</a>. 
Taiwan Semiconductor&#8217;s market cap first crossed the <a href="https://www.benzinga.com/news/24/07/39733017/taiwan-semiconductor-joins-the-trillion-dollar-club-surpassing-tesla-report">trillion-dollar threshold in July</a>. It has since contracted to roughly $820 billion — a stone&#8217;s throw away from Broadcom&#8217;s $867 billion. 
Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) are among the club&#8217;s current members after their market caps exceeded a trillion dollars, fueled <a href="https://www.benzinga.com/topic/artificial-intelligence">by AI advancements</a>.
With TSM and Broadcom both driving critical innovations in AI semiconductors, we ask: Which company&#8217;s market cap will attain nine zeros next?
<h2 class="wp-block-heading">TSMC: AI-Driven Chipmaker Poised For Growth</h2>
Taiwan Semiconductor stands as the world's largest contract chipmaker, leading the market with its 3nm and 5nm technology. These chips are integral for AI workloads, fueling AI giants like Nvidia and Apple.
This has propelled TSM's stock by over 83.3% year-to-date and 105.39% in the past year.
Analysts from Needham and Susquehanna maintain Overweight ratings, with an average price target of $236.67, implying 27.15% upside. A price at that level would push TSM's market cap to over $1.23 trillion, positioning it to re-join the trillion-dollar club.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png" alt="" class="wp-image-589674" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111709/Screenshot-2024-10-10-at-8.40.59-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, TSMC is also in a bullish trend with buying pressure across its eight, 20, 50 and 200-day moving averages, all signaling continued upward momentum. 
TSM&#8217;s stock currently trades at $186.33, supported by a simple moving average, or SMA, (50-day) of $170.55 and a SMA (200-day) of $149.54, indicating positive technical indicators.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/10/41245350/nvidia-poised-to-overtake-apple-as-worlds-most-valuable-company-how-much-jensen-huangs-company-n">Nvidia Poised To Overtake Apple As World&#8217;s Most Valuable Company</a>
<h2 class="wp-block-heading">Broadcom: AI Infrastructure Play With Solid Momentum</h2>
Broadcom is capitalizing on the AI boom through its extensive semiconductor solutions for data centers, networking infrastructure, and real-time analytics. 
Its stock is up 69.28% year-to-date and 114.05% in the past year. Despite bullish ratings, its projected upside falls short of TSM. Analysts from Cantor Fitzgerald, Truist Securities, and UBS see AVGO reaching $200, implying an 8.80% upside, which would push its market cap to $934 billion.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="456" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png" alt="" class="wp-image-589675" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/10111713/Screenshot-2024-10-10-at-8.41.08-PM-300x217.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent101024&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, Broadcom is also trending positively, with its current price of $184.40 supported by moving averages, such as its 50-day SMA of $161.82 and 200-day SMA of $142.55. However, it still lags behind TSM's stronger growth trajectory.
<h2 class="wp-block-heading">TSMC Could Outpace Broadcom In the Trillion-Dollar Race</h2>
While both stocks are positioned to benefit from AI, TSMC has the edge, with superior technical indicators and greater market cap potential. 
With an imminent leap toward $1.23 trillion in market cap if it meets analysts&#8217; upside potential, TSM appears more likely to reach the trillion-dollar club before Broadcom.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41271262/broadcom-micron-traders-get-new-tools-with-direxions-latest-leveraged-bull-and-bear-etfs">Broadcom, Micron Traders Get New Tools With Direxion&#8217;s Latest Leveraged Bull And Bear ETFs</a></li>
</ul>

Technicals

AAPL

AVGO

MSFT

NVDA

Taiwan Semiconductor Vs. Broadcom: Who Will Be The Next Trillion-Dollar AI Giant?

Live On CNBC, Kevin Simpson Announces Sold Walmart Covered Call

BMO Capital analyst David Gagliano maintains Peabody Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTU#NYSE">BTU</a>) with a Market Perform and raises the price target from $25 to $26.

BMO Capital Maintains Market Perform on Peabody Energy, Raises Price Target to $26

Investors with a lot of money to spend have taken a bullish stance on NextEra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEE#NYSE">NEE</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NEE, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for NextEra Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 50% bullish and 37%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $174,303, and 3 are calls, for a total amount of $190,320.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $95.0 for NextEra Energy over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for NextEra Energy's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of NextEra Energy's whale activity within a strike price range from $80.0 to $95.0 in the last 30 days. 
<h3>NextEra Energy Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577326_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$6.35</td>
<td>$6.1</td>
<td>$6.35</td>
<td>$82.50</td>
<td>$101.6K</td>
<td>2.0K</td>
<td style="text-align: right;">169</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.3</td>
<td>$3.2</td>
<td>$3.2</td>
<td>$95.00</td>
<td>$46.7K</td>
<td>635</td>
<td style="text-align: right;">147</td>
</tr>
<tr>
<td>NEE</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$4.35</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$82.50</td>
<td>$42.0K</td>
<td>4.6K</td>
<td style="text-align: right;">218</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.81</td>
<td>$2.7</td>
<td>$2.81</td>
<td>$80.00</td>
<td>$41.5K</td>
<td>3.1K</td>
<td style="text-align: right;">152</td>
</tr>
<tr>
<td>NEE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/18/24</td>
<td>$0.73</td>
<td>$0.67</td>
<td>$0.69</td>
<td>$80.00</td>
<td>$34.5K</td>
<td>8.6K</td>
<td style="text-align: right;">587</td>
</tr>
</tbody>
</table>

<h3>About NextEra Energy</h3>
NextEra Energy's regulated utility, Florida Power &amp; Light, is the largest rate-regulated utility in Florida. The utility distributes power to nearly 6 million customer accounts in Florida and owns 34 gigawatts of generation. FP&amp;L contributes roughly 70% of NextEra's consolidated operating earnings. NextEra Energy Resources, the renewable energy segment, generates and sells power throughout the United States and Canada with more than 34 GW of generation capacity, including natural gas, nuclear, wind, and solar.
After a thorough review of the options trading surrounding NextEra Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of NextEra Energy</h3>
<ul>
<li>Trading volume stands at 2,865,668, with NEE's price up by 1.13%, positioned at $81.49.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>Professional Analyst Ratings for NextEra Energy</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $85.66666666666667.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Jefferies has revised its rating downward to Hold, adjusting the price target to $87. 
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Equal-Weight rating on NextEra Energy with a target price of $80. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for NextEra Energy, targeting a price of $90. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for NextEra Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Market Whales and Their Recent Bets on NEE Options

High-rolling investors have positioned themselves bearish on ADMA Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADMA#NASDAQ">ADMA</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in ADMA often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 14 options trades for ADMA Biologics. This is not a typical pattern.
The sentiment among these major traders is split, with 21% bullish and 71% bearish. Among all the options we identified, there was one put, amounting to $40,000, and 13 calls, totaling $467,143.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $14.0 to $17.5 for ADMA Biologics during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ADMA Biologics's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ADMA Biologics's whale trades within a strike price range from $14.0 to $17.5 in the last 30 days. 
<h3>ADMA Biologics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577321_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.8</td>
<td>$2.4</td>
<td>$2.8</td>
<td>$17.50</td>
<td>$56.0K</td>
<td>3.5K</td>
<td>818</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.75</td>
<td>$2.15</td>
<td>$2.75</td>
<td>$17.50</td>
<td>$55.0K</td>
<td>3.5K</td>
<td>618</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$5.5</td>
<td>$4.4</td>
<td>$4.95</td>
<td>$14.00</td>
<td>$49.5K</td>
<td>120</td>
<td>103</td>
</tr>
<tr>
<td>ADMA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.2</td>
<td>$2.0</td>
<td>$2.2</td>
<td>$17.50</td>
<td>$44.0K</td>
<td>3.5K</td>
<td>214</td>
</tr>
<tr>
<td>ADMA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$0.5</td>
<td>$0.2</td>
<td>$0.5</td>
<td>$15.00</td>
<td>$40.0K</td>
<td>1</td>
<td>2.6K</td>
</tr>
</tbody>
</table>

<h3>About ADMA Biologics</h3>
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Having examined the options trading patterns of ADMA Biologics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>ADMA Biologics's Current Market Status</h3>
<ul>
<li>With a volume of 12,172,914, the price of ADMA is down -18.28% at $16.61. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 27 days.</li>
</ul>
<h3>Professional Analyst Ratings for ADMA Biologics</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $20.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $20. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ADMA Biologics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

ADMA

This Is What Whales Are Betting On ADMA Biologics

Harmony Gold Mining shares are trading higher after JP Morgan upgraded the stock from Underweight to Neutral and raised its price target from $4.9 to $8.2.

Whales with a lot of money to spend have taken a noticeably bullish stance on CVS Health.
Looking at options history for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) we detected 12 trades.
If we consider the specifics of each trade, it is accurate to state that 66% of the investors opened trades with bullish expectations and 25% with bearish.
From the overall spotted trades, 2 are puts, for a total amount of $179,610 and 10, calls, for a total amount of $1,201,272.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $60.0 to $70.0 for CVS Health over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for CVS Health options trades today is 5602.57 with a total volume of 29,356.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for CVS Health's big money trades within a strike price range of $60.0 to $70.0 over the last 30 days.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728577316_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/01/24</td>
<td>$0.9</td>
<td>$0.79</td>
<td>$0.9</td>
<td>$69.00</td>
<td>$450.0K</td>
<td>108</td>
<td>4</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$4.05</td>
<td>$4.0</td>
<td>$4.02</td>
<td>$63.00</td>
<td>$189.1K</td>
<td>5.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$65.00</td>
<td>$139.6K</td>
<td>6.0K</td>
<td>943</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/11/24</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.44</td>
<td>$63.00</td>
<td>$119.0K</td>
<td>5.1K</td>
<td>285</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/11/24</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$4.0</td>
<td>$63.00</td>
<td>$106.3K</td>
<td>5.1K</td>
<td>6.6K</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
Having examined the options trading patterns of CVS Health, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is CVS Health Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,013,488, with CVS's price up by 1.35%, positioned at $66.86.</li>
<li>RSI indicators show the stock to be may be overbought.</li>
<li>Earnings announcement expected in 27 days.</li>
</ul>
<h3>What The Experts Say On CVS Health</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $73.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Evercore ISI Group has decided to maintain their Outperform rating on CVS Health, which currently sits at a price target of $75. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $62. 
&#x2A; In a positive move, an analyst from Barclays has upgraded their rating to Overweight and adjusted the price target to $82. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Neutral, setting a price target of $62. 
&#x2A; An analyst from TD Cowen upgraded its action to Buy with a price target of $85. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About CVS Health

Exicure (XCUR) has provided an update. Exicure, Inc. has announced that it has been granted an extension to remain listed on the Nasdaq, provided i...

Exicure Granted Conditional Nasdaq Listing Extension

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to start off the final trading day of the week with a breakdown of the biggest pre-market stock movers for Friday morning!



Moving stocks this morning are earnings reports, a failed merger deal, delisting updates and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is rocketing more than 159% as the robot maker <a href="https://www.nasdaq.com/press-release/vsee-health-and-ava-robotics-partner-develop-telepresence-solutions-hospital">plans for telepresence solutions</a> for the inpatient intensive care market.</li>



<li>Adagio Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/adgm-stock-quote/">ADGM</a>) shares are soaring close to 36% following its <a href="https://www.businesswire.com/news/home/20240731222906/en/Adagio-Medical-Announces-the-Closing-of-the-Business-Combination-with-ARYA-IV-Creating-a-Publicly-Traded-Company-Focused-on-the-Innovative-Technologies-for-Treatment-of-Cardiac-Arrhythmias">recent public debut</a>.</li>



<li>Akanda (NASDAQ:<a href="https://investorplace.com/stock-quotes/akan-stock-quote/">AKAN</a>) stock is surging over 35% alongside heavy pre-market trading.</li>



<li>Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) shares are gaining more than 29% on a <a href="https://www.businesswire.com/news/home/20240801299565/en/Exicure-Inc.-Receives-Positive-Listing-Determination-from-Nasdaq">positive listing update</a> from the Nasdaq Capital Market.</li>



<li>Australian Oilseeds (NASDAQ:<a href="https://investorplace.com/stock-quotes/coot-stock-quote/">COOT</a>) stock is rising 25% after announcing a <a href="https://www.nasdaq.com/press-release/australian-oilseeds-announces-appointment-new-independent-auditor-2024-08-01">new independent auditor</a>.</li>



<li>Tandem Diabetes Care (NASDAQ:<a href="https://investorplace.com/stock-quotes/tndm-stock-quote/">TNDM</a>) shares are increasing nearly 25% with the release of its <a href="https://www.nasdaq.com/press-release/tandem-diabetes-care-announces-second-quarter-2024-financial-results-and-increases">Q2 earnings report</a>.</li>



<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is heading over 23% higher with <a href="https://www.nasdaq.com/press-release/vaccinex-reports-positive-data-signal-ad-phase-1b-2-trial-pepinemab-alzheimers">recent clinical trial news</a>.</li>



<li>AGBA Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/agba-stock-quote/">AGBA</a>) shares are climbing more than 13% without any clear news this morning.</li>



<li>Venus Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/vero-stock-quote/">VERO</a>) stock is jumping over 13% on Friday morning.</li>



<li>Integral Ad Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/ias-stock-quote/">IAS</a>) shares are up 13% with its <a href="https://www.nasdaq.com/press-release/ias-reports-second-quarter-2024-financial-results-2024-08-01">latest earnings news</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Gamer Pakistan (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/">GPAK</a>) stock is plummeting almost 47% <a href="https://www.pr.com/press-release/917157#:~:text=(Nasdaq%3AGPAK)%20(GPAK,and%20that%20trading%20of%20the">alongside a delisting notice</a>.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are diving more than 37% with the <a href="https://www.nasdaq.com/press-release/fresh-vine-wine-inc-and-notes-live-inc-mutually-agree-terminate-merger-agreement-2024">termination of a merger agreement</a>.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) stock is tumbling over 30% as Badcock Home Furniture &amp; More <a href="https://nypost.com/2024/08/01/business/major-furniture-chain-badcock-to-shut-all-its-stores-after-120-years/">shuts down all of its stores</a>.</li>



<li>Greenlane (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnln-stock-quote/">GNLN</a>) shares are taking a more than 24% beating on plans for a <a href="https://www.stocktitan.net/news/GNLN/greenlane-announces-board-s-approval-of-reverse-stock-split-9yehmvs5r4ed.html">reverse stock split</a>.</li>



<li>Procore Technologies (NYSE:<a href="https://investorplace.com/stock-quotes/pcor-stock-quote/">PCOR</a>) stock is dropping 22% alongside its <a href="https://www.nasdaq.com/press-release/procore-announces-second-quarter-2024-financial-results-2024-08-01">Q2 earnings report</a>.</li>



<li>Estrella Immunopharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/esla-stock-quote/">ESLA</a>) shares are sliding close to 21% on Friday morning.</li>



<li>Intel (NASDAQ:<a href="https://investorplace.com/stock-quotes/intc-stock-quote/">INTC</a>) stock is falling over 20% after releasing its <a href="https://www.theverge.com/2024/8/1/24210656/intel-is-laying-off-over-10000-employees-and-will-cut-10-billion-in-costs">Q2 earnings report</a>.</li>



<li>Smith Micro Software (NASDAQ:<a href="https://investorplace.com/stock-quotes/smsi-stock-quote/">SMSI</a>) shares are decreasing more than 19% with its <a href="https://seekingalpha.com/article/4709513-smith-micro-software-inc-smsi-q2-2024-earnings-call-transcript">latest earnings report</a>.</li>



<li>GraniteShares 2x Long AMZN Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzz-stock-quote/">AMZZ</a>) stock is slipping over 17%.</li>



<li>Snap (NYSE:<a href="https://investorplace.com/stock-quotes/snap-stock-quote/">SNAP</a>) shares close out our pre-market stock movers down more than 17% <a href="https://www.cnbc.com/2024/08/01/snap-shares-plunge-over-20percent-af.html">on weak guidance</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-aug-2nd/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

VSee Health, Dermata Therapeutics, and Exicure, Inc. are the 3 Penny Stocks to watch on August 6, based on&nbsp;TipRanks' Penny Stock Screener tool...

3 Penny Stocks to Watch Now, 8/6/24

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Exicure (NASDAQ:<a href="https://investorplace.com/stock-quotes/xcur-stock-quote/">XCUR</a>) just reported results for the second quarter of 2024.<ul><li>Exicure reported earnings per share of -7 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/xcur-stock-earnings-exicure-for-q2-of-2024/">XCUR Stock Earnings: Exicure Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

XCUR Stock Earnings: Exicure Reported Results for Q2 2024

Exicure reports Q2 results

Exicure to implement reverse stock split

Exicure (XCUR) has shared an update. Exicure, Inc. has announced a one-for-five reverse stock split effective August 27, 2024, after obtaining shar...

Exicure Announces Reverse Stock Split and Shareholder Approvals

Exicure receives extension from Nasdaq hearings panel

Exicure ( ($XCUR) ) has provided an announcement. Exicure, Inc. has been granted an extension by the Nasdaq Hearings Panel to continue its listing,...

Exicure Granted Extension for Nasdaq Compliance Deadline

The latest announcement is out from Exicure ( ($XCUR) ). Exicure, Inc. has successfully sold its spherical nucleic acid technology and related rese...

Exicure Divests Technology to Flashpoint, Secures Royalties

ADGM

AGBA

AKAN

AMZZ

CONN

COOT

DRMA

ESLA

GNLN

GPAK

INTC

PCOR

SMSI

SNAP

TNDM

VCNX

VERO

VINE

VSEE

Press Releases

Exicure, Inc. Reports Full Year 2023 Financial Results

Exicure, Inc. Reports First Quarter 2024 Financial Results

Exicure, Inc. Receives Positive Listing Determination from Nasdaq

Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics

Exicure, Inc. Reports Second Quarter 2024 Financial Results

Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting

Exicure, Inc. Announces 1-for-5 Reverse Stock Split

Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation

Comments

Exicure

Notizie

Ultime notizie per Exicure (NASDAQ:XCUR) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO